705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 31; p. S556
Main Authors Msaouel, P., Siefker-Radtke, A.O., Sweis, R., Mao, S., Rosenberg, J.E., Vaishampayan, U.N., Kalebasty, A. Rezazadeh, Pili, R., Bupathi, M., Nordquist, L.T., Shaffer, D.R., Davis, N., Zhang, T., Gandhi, S., Christensen, J., Shazer, R., Yan, X., Winter, M., Der-Torossian, H., Iyer, G. Vasudeva
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2020
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.08.777